小细胞肺癌异质性和表型可塑性的挑战
Kathryn L Simpson1,2,3, Dominic G Rothwell2,3, Fiona Blackhall3,4,5
1SCLC Biology Group, Cancer Research UK Manchester Institute, Manchester, UK.
Nature reviews. Cancer
|April 10, 2025
概括
小细胞肺癌 (SCLC) 是具有侵略性的,但新的研究揭示了分子脆弱性. 了解SCLC异质性和可塑性可能会导致个性化疗法和改进的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 小细胞肺癌 (SCLC) 是一种高度攻击性的神经内分泌癌症,存活率较低.
- 目前的免疫疗法提供的益处有限,预测性生物标志物稀缺.
- 最近的进展包括DLL3向治疗和改进的患者模型.
研究的目的:
- 绘制和理解SCLC的异质性和分子脆弱性.
- 探索表型可塑性在SCLC进展和抵抗中的作用.
- 确定开发个性化疗法和生物标志物的机会.
主要方法:
- 对患者衍生模型,瘤生物库和分子分析数据的分析.
- 基于转录因子 (ASCL1,NEUROD1,POU2F3) 和免疫特征的SCLC分子亚型的研究.
- 检查表型可塑性,包括由NOTCH信号驱动的神经内分泌到非神经内分泌的过渡.
主要成果:
- 在p53/RB1损失之外,SCLC表现出显著的瘤间和瘤内异质性.
- 关键的失调途径包括MYC家族,YAP1,NOTCH,BCL2和表观遗传调节器.
- 现型可塑性,特别是NOTCH驱动的过渡,与进展,化学抵抗和转移相关.
结论:
- 了解SCLC的分子格局,包括转录因子亚型和可塑性,至关重要.
- 针对已识别的分子漏洞提供了个性化治疗策略的潜力.
- 开发液体和组织生物标志物对于指导SCLC治疗至关重要.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.6K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.6K
Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer
47.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
47.2K
Cancers Originate from Somatic Mutations in a Single Cell
11.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.3K


